Skip to main content
Contact Us
Subscribe
E-Edition
76°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pfizer Inc.
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
November 18, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
November 18, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Completes Acquisition of Trillium Therapeutics
November 17, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio
November 17, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate
November 16, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
November 16, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 10, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
November 05, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
PFIZER REPORTS THIRD-QUARTER 2021 RESULTS
November 02, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
October 29, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer and BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs
October 28, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years
October 26, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
October 21, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults
October 20, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
October 15, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Japan’s MHLW Approves Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis
September 30, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
September 29, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
September 28, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program
September 27, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults
September 27, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analysts
September 23, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares Fourth-Quarter 2021 Dividend
September 23, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster
September 22, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries
September 22, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 20, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
September 20, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
September 17, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis
September 09, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences
September 07, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
September 02, 2021
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.